California Public Employees Retirement System Continues to Hold Stake in Fibrocell Science Inc (FCSC)
California Public Employees Retirement System held its stake in Fibrocell Science Inc (NASDAQ:FCSC) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,333 shares of the company’s stock at the close of the second quarter. California Public Employees Retirement System owned 0.25% of Fibrocell Science worth $146,000 as of its most recent filing with the Securities and Exchange Commission.
Separately, Creative Planning boosted its position in Fibrocell Science by 395.3% during the second quarter. Creative Planning now owns 61,090 shares of the company’s stock worth $245,000 after purchasing an additional 48,755 shares in the last quarter. 55.81% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have issued reports on FCSC. Canaccord Genuity reiterated a “buy” rating and set a $7.00 price target (up previously from $3.00) on shares of Fibrocell Science in a research report on Monday, September 11th. HC Wainwright restated a “buy” rating and issued a $5.70 target price on shares of Fibrocell Science in a research report on Friday, September 15th. Zacks Investment Research upgraded Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Friday, September 15th. Finally, ValuEngine downgraded Fibrocell Science from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $5.21.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Stock Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related stocks with our FREE daily email newsletter.